|
1.
|
American Cancer Society: Breast Cancer
Facts and Figures 2011–2012. ACS; Atlanta, GA: 2012
|
|
2.
|
DeSantis C, Siegel R, Bandi P, et al:
Breast cancer statistics, 2011. CA Cancer J Clin. 61:409–418. 2011.
View Article : Google Scholar
|
|
3.
|
Mariani G: New developments in the
treatment of metastatic breast cancer: from chemotherapy to
biological therapy. Ann Oncology. 16(Suppl 2): 191–194. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Ambudkar SV, Sarfaty CK, Sauna ZE, et al:
P-glycoprotein: from genomics to mechanism. Oncogene. 22:7468–7485.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Larsen AK, Escargueil AE and Skladanowski
A: Resistance mechanisms associated with altered intracellular
distribution of anticancer agents. Pharmacol Ther. 85:217–229.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Molinari A, Calcabrini A, Meschini S, et
al: Subcellular detection and localization of the drug transporter
P-glycoprotein in cultured tumor cells. Curr Protein Pept Sci.
3:653–670. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Kars MD, Işeri OD and Gündüz U: A
microarray based expression profiling of paclitaxel and vincristine
resistant MCF-7 cells. Eur J Pharmacol. 657:4–9. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Xu JW, Li QQ, Tao LL, et al: Involvement
of EGFR in the promotion of malignant properties in multidrug
resistant breast cancer cells. Int J Oncol. 39:1501–1509.
2011.PubMed/NCBI
|
|
9.
|
Tainton KM, Smyth MJ, Jackson JT, et al:
Mutational analysis of P-glycoprotein: suppression of caspase
activation in the absence of ATP-dependent drug efflux. Cell Death
Differ. 11:1028–1037. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Howell A, DeFriend D, Robertson JFR, et
al: Response to a specific antiestrogen (ICI 182,780) in
tamoxifen-resistant breast cancer. Lancet. 345:29–30. 1995.
View Article : Google Scholar
|
|
11.
|
Howell A, Howell SJ and Evans DG: New
approaches to the endocrine prevention and treatment of breast
cancer. Cancer Chemother Pharmacol. 52:S39–S44. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Labbozzetta M, Notarbartolo M, Poma P, et
al: Curcumin as a possible lead compound against
hormone-independent, multidrug-resistant breast cancer. Ann NY Acad
Sci. 1155:278–283. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Sui M, Huang Y, Park BH, et al: Estrogen
receptor α mediates breast cancer cell resistance to paclitaxel
through inhibition of apoptotic cell death. Cancer Res.
67:5337–5344. 2007.
|
|
14.
|
Smith L, Watson BM, O’Kane SL, et al: The
analysis of doxorubicin resistance in human breast cancer cells
using antibody microarrays. Mol Cancer Ther. 5:2115–2120. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Sharpe JC, Arnoult D and Youle RJ: Control
of mitochondrial permeability by Bcl-2 family members. Biochim
Biophys Acta. 1644:107–113. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Zamzami N, Brenner C, Marzo I, et al:
Subcellular and submitochondrial mode of action of Bcl-2-like
oncoproteins. Oncogene. 16:2265–2282. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Kowaltowski AJ, Cosso RG, Campos CB, et
al: Effect of Bcl-2 overexpression on mitochondrial structure and
function. J Biol Chem. 277:42802–42807. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Calcabrini A, Martínez JM, González L, et
al: Inhibition of proliferation and induction of apoptosis in human
breast cancer cells by lauryl gallate. Carcinogenesis.
27:1699–1712. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Tarasiuk J, Majewska E, Seksek O, et al:
The role of structural factors in the kinetics of cellular uptake
of pyrazoloacridines and pyrazolopyrimidoacridines: Implications
for overcoming multidrug resistance towards leukaemia K562/DOX
cells. Biochem Pharmacol. 68:1815–1823. 2004.
|
|
20.
|
Pourpak A, Landowski TH and Dorr RT:
Ethonafide-induced cytotoxicity is mediated by topoisomerase II
inhibition in prostate cancer cells. J Pharmacol Exp Ther.
321:1109–1117. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Xie SQ, Hu GQ, Zhang ZQ, et al:
Anti-tumour effects of HL-37, a novel anthracene derivative,
in-vivo and in-vitro. J Pharm Pharmacol. 60:213–219. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Zhang G, Fang L, Zhu L, et al: Syntheses
and biological activities of 3′-azido disaccharide analogues of
daunorubicin against drug-resistant leukemia. J Med Chem.
49:1792–1799. 2006.
|
|
23.
|
Kim R: Recent advances in understanding
the cell death pathways activated by anticancer therapy. Cancer.
103:1551–1560. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Teixeira C, Reed JC and Pratt MA: Estrogen
promotes chemo-therapeutic drug resistance by a mechanism involving
Bcl-2 proto-oncogene expression in human breast cancer cells.
Cancer Res. 55:3920–3907. 1995.PubMed/NCBI
|
|
25.
|
Lu M, Lopez RM, Nakajo S, et al:
Expression of estrogen receptor α, retinoic acid receptor a and
cellular retinoic acid binding protein II genes is coordinately
regulated in human breast cancer cells line. Oncogene.
24:4362–4369. 2005.
|
|
26.
|
Alle KM, Henshall SM, Field AS, et al:
Cyclin D1 protein is overexpressed in hyperplasia and intraductal
carcinoma of the breast. Clin Cancer Res. 4:847–854.
1998.PubMed/NCBI
|
|
27.
|
Van Diest PJ, Michalides RJ, Jannink L, et
al: Cyclin D1 expression in invasive breast cancer. Correlations
and prognostic value. Am J Pathol. 150:705–711. 1997.PubMed/NCBI
|
|
28.
|
Gillett C, Fantl V, Smith R, et al:
Amplification and overexpression of cyclin D1 in breast cancer
detected by immunohistochemical staining. Cancer Res. 54:1812–1817.
1994.PubMed/NCBI
|
|
29.
|
Naidu R, Wahab NA, Yadav MM, et al:
Expression and amplification of cyclin D1 in primary breast
carcinomas: relationship with histopathological types and
clinico-pathological parameters. Oncol Rep. 9:409–416.
2002.PubMed/NCBI
|
|
30.
|
Lavelle D, DeSimone J, Hankewych M, et al:
Decitabine induces cell cycle arrest at the G1 phase via p21WAF1
and the G2/M phase via the p38 MAP kinase pathway. Leuk Res.
27:999–1007. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Sandor V, Senderowicz A, Mertins S, et al:
p21-dependent G1 arrest with downregulation of cyclin D1 and
upregulation of cyclin E by the histone deacetylase inhibitor
FR901228. Br J Cancer. 83:817–825. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Marqués-Gallego P, Contaldi S, den Dulk H,
et al: Relevance of the leaving group for antitumor activity of new
platinum(II) compounds containing anthracene derivatives as a
carrier ligand. J Inorg Biochem. 103:1602–1608. 2009.PubMed/NCBI
|
|
33.
|
Nazarov AA, Risse J, Ang WH, et al:
Anthracene-tethered ruthenium(II) arene complexes as tools to
visualize the cellular localization of putative organometallic
anticancer compounds. Inorg Chem. 51:3633–33639. 2012. View Article : Google Scholar
|
